Condition (MeSH)
Giant Cell Tumor of Tendon Sheath
ClinicalTrials.gov lists 30 trials for Giant Cell Tumor of Tendon Sheath or a narrower condition beneath it. Daiichi Sankyo has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
22 of the 30 trials are tagged with Giant Cell Tumor of Tendon Sheath itself; the rest are tagged with a narrower condition beneath it.
When did Giant Cell Tumor of Tendon Sheath trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 2 |
| 2021 | 5 |
| 2020 | 5 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 2 |
| 2015 | 2 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Giant Cell Tumor of Tendon Sheath trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 2 |
| Phase 2 | 10 |
| Phase 3 | 5 |
| Phase 4 | 2 |
| Not applicable | 1 |
| Observational | 5 |
How many Giant Cell Tumor of Tendon Sheath trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 6 |
| Active, not recruiting | 5 |
| Completed | 14 |
| Terminated | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Giant Cell Tumor of Tendon Sheath trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Daiichi Sankyo | 6 |
| AmMax Bio, Inc. | 3 |
| Deciphera Pharmaceuticals, LLC | 3 |
| Abbisko Therapeutics Co, Ltd | 2 |
| Daiichi Sankyo Co., Ltd. | 2 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Giant Cell Tumor of Tendon Sheath? (8)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Pexidartinib | 6 |
| Pimicotinib | 4 |
| Vimseltinib | 3 |
| Cabiralizumab | 1 |
| Emactuzumab | 1 |
Showing 5 of 8 drugs.
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| AMB-05X | 3 |
| Nilotinib Pill | 2 |
| D. Midazolam | 1 |
| PLX73086 | 1 |
| Indocyanine Green dye | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Giant Cell Tumor of Tendon Sheath trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Abdominal pain | 4 | 2 |
| Cellulitis | 4 | 1 |
| Migraine | 4 | 2 |
| Blood bilirubin increased | 3 | 1 |
| Hepatic enzyme abnormal | 3 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Giant Cell Tumor of Tendon Sheath? (17)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature review. | Future oncology (London, England) | 2025 | Yes |
| Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet (London, England) | 2024 | Yes |
| Use of neoadjuvant pexidartinib with limb salvage surgery for diffuse tenosynovial giant cell tumor: A case report. | Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association | 2024 | Yes |
| The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor. | Future oncology (London, England) | 2024 | Yes |
| Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts. | Cancer treatment reviews | 2023 | Yes |
Showing 5 of 17 publications.
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Tenosynovial giant cell tumor | Point prevalence | 1-5 / 10 000 | Europe | Not stated | Exact |
| Tenosynovial giant cell tumor | Point prevalence | 1-5 / 10 000 | Europe | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Tenosynovial giant cell tumor | 66627 | Exact | Orphadata Science knowledge files, Product 1 |
| Tenosynovial giant cell tumor | 66627 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.